Twenty-five biotechs have used the IPO route to go public this year—with five of those debuts occurring this month alone.

Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3% ...

Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode… Read More ...

U.S. FDA 510 (k) cleared and Health Canada approved revyve® Antimicrobial Wound Gel Spray The presentation, entitled ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

PBE concentrates on 31 companies and offers a higher dividend yield, while IBBQ spreads risk across 251 holdings at a ...

Chief Market Strategist at SlateStone Wealth, Llc Kenny Polcari joins Stuart Varney to discuss Bitcoin’s rally, Moderna’s ...

A top Barclays biopharma analyst says the forces that froze biotech dealmaking are breaking apart, and the pharma giants ...

WHX to take place from 25–28 January 2027 across Dubai Exhibition Centre, Expo City and Dubai World Trade Centre By ...

Sovereign capital, guaranteed offtake, and localization mandates are reshaping how biotech deals get structured in the Gulf, ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Researchers are increasingly using AI and biotechnology tools to better understand the ...

A Seattle biotech built on University of Washington research has won a $245 million patent judgment against Guardant Health ...